HIV heart risk targeted: new drug trial aims to quiet arterial inflammation
NCT ID NCT05488431
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether bempedoic acid, a cholesterol-lowering drug, can reduce artery inflammation and improve heart health in people with HIV. About 121 adults aged 40 and older with well-controlled HIV and at least one heart disease risk factor will receive either the drug or a placebo for 52 weeks. Researchers will use advanced imaging to measure changes in arterial inflammation and plaque buildup.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
San Francisco General Hospital
RECRUITINGSan Francisco, California, 94110, United States
-
UCLA Center for Clinical AIDS Research and Education (CARE)
RECRUITINGLos Angeles, California, 90095, United States
-
UT Health Houston
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity